Biocept Inc. (NASDAQ: BIOC) stock fell -8.98% on Monday to $1.52 against a previous-day closing price of $1.67. With 0.69 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.92 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.7799 whereas the lowest price it dropped to was $1.5000. The 52-week range on BIOC shows that it touched its highest point at $29.18 and its lowest point at $0.80 during that stretch. Beta for the stock currently stands at 0.75.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIOC was up-trending over the past week, with a rise of 17.83%, but this was up by 66.32% over a month. Three-month performance dropped to -21.24% while six-month performance fell -78.51%. The stock lost -94.40% in the past year, while it has lost -90.44% so far this year. A look at the trailing 12-month EPS for BIOC yields -50.69 with Next year EPS estimates of -1.38. EPS is expected to grow by 40.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 61.00%.
Float and Shares Shorts:
At present, 2.63 million BIOC shares are outstanding with a float of 2.63 million shares on hand for trading. On Aug 30, 2023, short shares totaled 16059.999999999998, which was 0.61% higher than short shares on Jul 30, 2023. In addition to Mr. Antonino Morales as the firm’s CEO, Pres & Director, Mr. Darrell Taylor Esq. serves as its Chief Legal Officer, Chief Compliance Officer, Corp. Sec. & Registered In-House Counsel.
Institutional Ownership:
Through their ownership of 1.98% of BIOC’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.71% of BIOC, in contrast to 0.33% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BIOC with 1.71% of the stake, Anson Funds Management LP holds 44,861 shares worth 44,861. A second-largest stockholder of BIOC, Boothbay Fund Management LLC, holds 23,529 shares, controlling over 0.90% of the firm’s shares. Tower Research Capital LLC is the third largest shareholder in BIOC, holding 5,389 shares or 0.21% stake. With a 0.17% stake in BIOC, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 4,434 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.11% of BIOC stock, is the second-largest Mutual Fund holder. It holds 2,952 shares valued at 2539.0. Fidelity Series Total Market Inde holds 0.03% of the stake in BIOC, owning 644 shares worth 554.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, BIOC reported revenue of $10.61M and operating income of -$5.10M. The EBITDA in the recently reported quarter was -$5.10M and diluted EPS was -$17.82.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIOC since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BIOC analysts setting a high price target of $330.00 and a low target of $330.00, the average target price over the next 12 months is $330.00. Based on these targets, BIOC could surge 21610.53% to reach the target high and rise by 21610.53% to reach the target low. Reaching the average price target will result in a growth of 21610.53% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded BIOC stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
